Treatment-resistant depression (TRD)
Sometimes depression doesn’t get better, even with treatment.
‘Treatment-resistant depression’ (TRD) is a condition in which individuals with major depressive disorder do not respond adequately to at least two different treatments.
Depression is the leading cause of disability and ill health worldwide. Up to two-thirds of people with depression are not helped by the first antidepressant medication they try. Up to a third of people with depression are failed by multiple attempts at treatment.
About our treatment-resistant depression clinical development programme
We are studying investigational psilocybin therapy (also known as psilocybin treatment) as a treatment for TRD. We have received FDA Breakthrough Therapy designation and Innovative Licensing and Access Pathway designation for our investigational COMP360 psilocybin for TRD.
We’re running a global clinical development programme of COMP360 psilocybin treatment for TRD.
Phase 2b study results
The New England Journal of Medicine published results from our phase 2b trial of investigational COMP360 psilocybin treatment for treatment-resistant depression
